Agenus Inc. Stock News

Agenus (AGEN) delivered earnings and revenue surprises of -62.50% and 46.30%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Agenus press release (AGEN): Q4 GAAP EPS of -$0.26 misses by $0.10.Revenue of $20.26M (-35.2% Y/Y) misses by $17.48M.Shares +1.85% PM.

Agenus' (AGEN) CEO Garo Armen on Q4 2021 Results - Earnings Call Transcript

LEXINGTON, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies and adjuvants designed to activate immune response to cancers and infections, today provided a corporate update and reported financial results for the fourth quarter and full year 2021.

Agenus (AGEN) delivered earnings and revenue surprises of -62.50% and 46.30%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

In today’s recent session, 0.66 million shares of the Agenus Inc. (NASDAQ:AGEN) have been traded, and its beta is 1.18. Most recently the company’s share price was $2.47, and it changed around $0.12 or 5.11% from the last close, which brings the market valuation of the company to $623.34M. AGEN at last check was trading … Why Agenus Inc. (NASDAQ: AGEN) Is A Stock Not To Be Discarded In 2022 Read More »

Agenus: Making Another Effort With The FDA

A long-awaited regulatory event sent the biotech's shares on a roller-coaster ride last year.

A long-awaited regulatory event sent the biotech's shares on a roller-coaster ride last year.

Investors need to pay close attention to Agenus (AGEN) stock based on the movements in the options market lately.

Agenus (AGEN) announced that Dr. Jennifer Buell, its President and Chief Operating Officer, resigned from her position at the company to become President and Chief Executive Officer at

LEXINGTON, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, adjuvants, and vaccines designed to activat

LEXINGTON, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, adjuvants, and vaccines designed to activate

Related Stocks: ARGX , MGNX , CUTR , RNA , FULC , ITOS , TMO , PEN , TNYA , SGHT , AADI , RCOR , PTGX , MDXG , CSTL , AGEN , ABUS , QDEL , TRIL , CHAQ , BCTG , ITMR , RACA ,